20 January 2026 - Top Stories

Australian healthtech news on 20 January 2026 spans robotics, patient data access, reforms to Medicare payments, telehealth governance, regional IT upgrades, and new medical devices. The thread is one of practical adoption, regulatory clarity and efforts to improve care coordination across state and national systems.

Intuitive Surgical’s da Vinci 5 has gained ARTG listing in Australia, expanding access to advanced robotic surgery. The system is described as a major upgrade with markedly higher computing capacity and improved imaging. Reported figures suggest about ten thousand times the processor power of earlier models and four times the colour and detail resolution, with Firefly imaging and a redesigned workstation enhancing intraoperative visuals.

My Health Record now lets patients view most pathology results on the day they see their clinician, accelerating patient access to test outcomes. Patients may also upload results to AI tools such as ChatGPT Health to check for abnormalities. Clinicians emphasise that AI should augment, not replace, clinical interpretation, and warn against misinterpretation without context.

On funding and administration, plans to phase out Medicare rebate cheques by mid-2028 were released, with a public consultation process under way. The proposal tightens gap-only billing to MBS services above a defined threshold (currently indexed at 697 dollars) and will retire the Pay Doctor Via Claimant system for new gaps, while preserving some 90-day payment delays.

A group led by Montu and including Rare Cancers Australia is urging the mandating of telehealth standards. The CARE framework they propose covers clinical care, administrative operations, resourcing and ethics, signalling potential moves toward stronger governance, interoperability and vendor accountability across telehealth platforms.

Regional cancer care moves toward digital automation with Charm Oncology Information Management System going live at Northeast Health Wangaratta. Funded by the Victorian Government and delivered by Magentus, Charm replaces paper-based prescribing and scheduling with an integrated, auditable workflow that promises lower administrative burden and more consistent data capture for outcomes tracking.

In product and public health terms, the TGA has approved neffy, a needle-free 2 mg adrenaline nasal spray for anaphylaxis, marking Australia’s first non-injectable option for emergency treatment. The nasal spray targets adults and children over four years and 15 kg, with nasal irritation and headaches among the common side effects. The move accompanies NSW’s plan to curb illicit tobacco through tighter retail controls, reflecting a broader regulatory push to reshape health risk management and surveillance across the country.